Fate Therapeutics, Inc. (FATE) has a negative trailing P/E of -1.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -92.95%.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.4 | 0.22 | 1.09 | 18.11 | - |
| 2017 | -6.0 | 2.09 | 3.32 | 62.47 | - |
| 2018 | -10.8 | -0.65 | 4.49 | 152.11 | - |
| 2019 | -13.6 | -0.67 | 5.45 | 124.95 | - |
| 2020 | -43.2 | -0.92 | 19.49 | 238.32 | - |
| 2021 | -26.1 | -3.92 | 8.17 | 99.27 | - |
| 2022 | -3.5 | -0.12 | 2.02 | 10.15 | - |
| 2023 | -2.3 | 0.05 | 1.00 | 5.79 | - |
| 2024 | -1.0 | 0.00 | 0.59 | 13.76 | - |
| 2025 | -0.9 | 0.03 | 0.56 | 17.56 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.05 | $4.4M | $-33.46M | -760.2% |
| 2017 | $-1.02 | $4.11M | $-42.95M | -1046.1% |
| 2018 | $-1.19 | $4.74M | $-66.6M | -1405% |
| 2019 | $-1.43 | $10.68M | $-97.71M | -914.9% |
| 2020 | $-2.07 | $31.43M | $-170.3M | -541.8% |
| 2021 | $-2.18 | $55.85M | $-206.3M | -369.4% |
| 2022 | $-2.63 | $96.3M | $-255.06M | -264.9% |
| 2023 | $-1.64 | $63.53M | $-160.93M | -253.3% |
| 2024 | $-1.64 | $13.63M | $-186.26M | -1366.5% |
| 2025 | $-1.15 | $6.65M | $-136.32M | -2051.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.13 | $-1.31 – $-0.64 | $5.96M | $3.58M – $9.54M | 9 |
| 2027 | $-1.07 | $-1.49 – $-0.37 | $5.79M | $3.86M – $8.69M | 7 |
| 2028 | $-1.06 | $-1.70 – $-0.57 | $6.9M | $6.65M – $7.15M | 5 |
| 2029 | $-0.95 | $-1.57 – $-0.54 | $64.68M | $43.12M – $97.02M | 1 |
| 2030 | $-0.53 | $-0.88 – $-0.30 | $182.36M | $121.57M – $273.54M | 1 |
